San Diego, United States
Novoron Bioscience is carving a niche in the biotechnology sector by pioneering a novel approach to drug development focused on repairing neurological damage. Their innovative work with lipoprotein-receptor drugs targets severe conditions like multiple sclerosis, spinal cord injuries, and Alzheimer's disease. Founded in 2014, the company is based in the United States and plays a significant role in the Biopharma and Pharmaceutical industries.
Their commitment to addressing some of the most intractable neurological diseases underscores their potential impact in the Health Care and Life Sciences fields. With a recent financial boost of $125.00K through a Convertible Note investment in August 2021 from Two Bear Capital, Novoron Bioscience is positioned to further its research and development efforts, maintaining strong progression in a highly competitive market.
